Abstract
Introduction
This analysis examines the historical and forecast performance for Gilead in
the prescription pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to purchase this research
- Benchmark Gilead' s performance against key rivals in the prescription
pharmaceutical sector
- See how Gilead' s HIV franchise will drive continued double-digit sales
growth for the company out to 2014
- Assess the impact of the company' s recently announced collaboration with
Tibotec for a ' second generation Atripla'
| 
View Cart
